Table 1.
Characteristics of those living with CHB (n = 83)
| Median age | 49 years | (IQR 40–59.5) |
|---|---|---|
| Male | 48 | (58%) |
| eAg status | ||
| Positive | 9 | (10.8%) |
| Negative | 68 | (81.9%) |
| Unknown | 6 | (7.2%) |
| eAb status | ||
| Positive | 59 | (71.1%) |
| Negative | 17 | (20.4%) |
| Unknown | 7 | (8.4%) |
| Currently receiving nucleos(t) ide analogue treatment for HBV | 13 | (15.6%) |
| Co-infection | ||
| HIV positive | 0 | (0%) |
| HCV positive | 0 | (0%) |
| HAV Immune | 63 | (75.9%) |
Values are in numbers and (percentage) unless otherwise stated. CHB Chronic hepatitis B infection; eAg, e-antigen; eAb, e-antibody, HAV Hepatitis A virus, HBV Hepatitis B virus, HCV Hepatitis C virus, HIV Human Immunodeficiency virus, IQR Interquartile range